SCHEMBL30973548

SCHEMBL30973548

Cc1c(Cl)nnc2c1c(F)cn2[C@@H]1CCCN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 5/20 0.42
EGFR P00533 3/20 0.42
ABL1 P00519 2/20 0.40
ABL2 P42684 2/20 0.40
BTK Q06187 4/20 0.39
SCN9A Q15858 1/20 0.38
HCAR1 Q9BXC0 1/20 0.37
P2RX7 Q99572 2/20 0.37
IL1B P01584 1/20 0.37
TRPV3 Q8NET8 1/20 0.37
FPR2 P25090 1/20 0.37
CNR1 P21554 1/20 0.36
CNR2 P34972 1/20 0.36
HPGDS O60760 1/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
KMT2A Q03164 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31265017 0.81 HCAR1 (0.44) SRCEGFRABL1ABL2BTK
SCHEMBL30973451 0.81 HCAR1 (0.40) SRCEGFRABL1ABL2BTK
SCHEMBL30973479 0.78 HTR6 (0.39) IL1B
SCHEMBL30994012 0.77 SRC (0.41) SRCEGFRABL1ABL2BTK
SCHEMBL19731467 0.77 SRC (0.54) SRCEGFRABL1ABL2BTK
SCHEMBL30994180 0.75 SRC (0.43) SRCEGFRABL1ABL2BTK
SCHEMBL15914127 0.74 SRC (0.53) SRCEGFRABL1ABL2BTK
SCHEMBL13858155 0.74 SRC (0.53) SRCEGFRABL1ABL2BTK
SCHEMBL14635891 0.74 SRC (0.53) SRCEGFRABL1ABL2BTK
SCHEMBL30994150 0.74 SRC (0.41) SRCEGFRABL1ABL2BTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4642784-A1 HETEROCYCLIC AND HETEROARYL COMPOUNDS AS INHIBITORS OF NLRP3 PTC Therapeutics, Inc. (US) 2025-11-05 EP disclosed
WO-2024145623-A1 HETEROCYCLIC AND HETEROARYL COMPOUNDS AS INHIBITORS OF NLRP3 PTC THERAPEUTICS, INC. (US) 2024-07-04 WO disclosed